Innovating Works

filtrando por convocatoria: HORIZON-MISS-2023-CANCER-01-03

DEFINITIVE: Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA tramitó un HORIZON EUROPE: HORIZON-MISS-2023-CANCER-01 HER2+ breast cancer affects around 390.000 women annually worldwide (i.e. 3 patients every 4 minutes). Over the last decade, polychemotherap...
2023-12-11 - 2028-11-30 | Financiado
iBeCHANGE: IBeCHANGE ADDRESSING PSYCHOSOCIAL AND LIFESTYLE RISK FACTORS TO PROMOTE PRIMARY CANCER PREVENTION... "Europe’s Beating Cancer Plan set has ambitious goals addressing key behavioral risk factors for cancer development, such as tobacco (target...
2023-12-11 - 2028-11-30 | Financiado
MELIORA: Multimodal Engagement and sustainable Lifestyle Interventions Optimizing breast cancer Risk reductio... MELIORA Consortium will jointly work with local actors at different levels for the realization of eight (8) in total tailor-made lifestyle i...
2023-12-08 - 2027-12-31 | Financiado
HIT-GLIO: Targeting tumour host interactions in paediatric malignant gliomas to reinvigorate immunity and impr... Paediatric high-grade gliomas (pHGGs) are malignant, deadly tumours developing in infants and children. Mutations in histone coding genes di...
2023-12-07 - 2027-11-30 | Financiado
RESOLVE: Residual disease assessment in hematologic malignancies to improve patient relevant outcomes across... "MeMeasurable residual disease (MRD) detected by multiparameter flow cytometry (MFC) has strong prognostic value in patients with the most f...
2023-12-13 - 2029-03-31 | Financiado
THRIVE: TUMOUR HOST INTERACTIONS IN LIVER CANCER OF CHILDHOOD AND ADULTS "Liver cancer is a major health problem with ~1 million cases diagnosed each year (~90,000 cases/year in Europe), and it is the 3rd cause of...
2023-12-11 - 2028-11-30 | Financiado
PREMIO COLLAB: Personalised response monitoring in oncology co creating clinical trials in advanced breast cancer PREMIO COLLAB’s vision is to prolong overall survival and improve the quality of life for patients with metastatic breast cancer (MBC) by pr...
2023-12-08 - 2029-12-31 | Financiado
MULTIR: MULti Tumour based prediction and manipulation of Immune Response Only few patients respond to tumor treatment as desired. Treatment heavily relies on host tumor interactions, including exploiting the host...
2023-12-07 - 2027-12-31 | Financiado
SUNRISE: SUstaiNable inteRventions and healthy behavIours for adoleScent primary prEvention of cancer with di... Primary prevention of cancer through behaviour changes in adolescence – a critical period in which many risk behaviours are initiated –, is...
2023-12-07 - 2028-04-30 | Financiado
MONALISA: A SIOPEN pragmatic clinical trial to MOnitor NeuroblastomA relapse with LIquid biopsy Sensitive Anal... High-risk neuroblastoma accounts for 15% of cancer related-deaths in children. Half of the >1500 patients yearly diagnosed with neuroblastom...
2023-12-07 - 2028-12-31 | Financiado
SPACETIME: SPatial Analysis of Cancer Evolution in the Tumour Immune MicroEnvironment STICHTING AMSTERDAM UMC tramitó un HORIZON EUROPE: HORIZON-MISS-2023-CANCER-01 The introduction of immune checkpoint therapy for Non-Small Cell Lung Cancer (NSCLC) has improved clinical outcomes. However, due to primary...
2024-06-03 - 2029-07-31 | Financiado
Arturo: Assessing the role of intratumoral microbiota in therapy responses using patient derived tumor on ch... INSTITUT CURIE tramitó un HORIZON EUROPE: HORIZON-MISS-2023-CANCER-01 "This action is part of the Cancer Mission cluster of projects on Understanding (tumour-host interactions)"". Challenge: Primary or acquired...
2024-06-06 - 2028-06-30 | Financiado